

# OPTIMA HEALTH PLAN

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process may be delayed.**

**Drug Requested:** Vioice® (alpelisib)

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

**Drug Name/Form/Strength:** \_\_\_\_\_

**Dosing Schedule:** \_\_\_\_\_ **Length of Therapy:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_ **ICD Code, if applicable:** \_\_\_\_\_

### **Quantity Limits:**

- 50 mg therapy pack = 1 tablet per day
- 125 mg therapy pack = 1 tablet per day
- 250 mg therapy pack = 56 tablets (1 box) per 28 days

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

**Initial Authorization: 6 months**

- ☐ Member is 2 years of age or older
- ☐ Requesting provider is an oncologist, having a specialty in treating patients with PIK3CA-Related Overgrowth Spectrum
- ☐ Member has a diagnosis of PIK3CA-Related Overgrowth Spectrum, confirmed by **BOTH** of the following:
  - ☐ Documented evidence for a PIK3CA gene mutation
  - ☐ Member has at least one target lesion identified on imaging
- ☐ Member's condition is severe or life-threatening requiring systemic therapy (**documentation of severe clinical manifestations include Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal [CLOVES], Facial Infiltrating Lipomatosis [FIL], Klippel-Trenaunay Syndrome [KTS], Megalencephaly-Capillary Malformation Polymicrogyria [MCAP]**)
- ☐ Member's age and weight meet **ONE** of the following:
  - ☐ Age 2-5 years: 50 mg (1 tablet) per day
  - ☐ Age 6-17 years: 125 mg (1 tablet) per day
  - ☐ Age > 18 years: 250 mg therapy pack (2 tablets) per day

(Continued on next page)

**Reauthorization: 12 months.** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Member is responding positively to therapy as evidenced by subsequent imaging scan with a reduction in sum of measurable lesion volume assessed across 1 to 3 target lesions (**radiological response defined as a  $\geq 20\%$  reduction from baseline in the sum of target lesion volume**)
- ☐ Member is **NOT** experiencing any toxicity from therapy (e.g., severe cutaneous adverse reactions, severe hyperglycemia, severe lung toxicity)
- ☐ Member's age and weight continues to meet **ONE** of the following (**Provider please note: If request is for a dose increase, new dose must NOT exceed any of the following**):
  - ☐ Age 2-5 years: 50 mg (1 tablet) per day
  - ☐ Age 6-17 years: 125 mg (1 tablet) per day
  - ☐ Age > 18 years: 250 mg therapy pack (2 tablets) per day

**Medication being provided by Specialty Pharmacy - PropriumRx**

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****

Member Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

\*Approved by Pharmacy and Therapeutics Committee: 7/21/2022

REVISED/UPDATED: 8/7/2022